UY32691A - Compuestos de 1h-imidazo-[4,5-c]-quinolinona - Google Patents

Compuestos de 1h-imidazo-[4,5-c]-quinolinona

Info

Publication number
UY32691A
UY32691A UY0001032691A UY32691A UY32691A UY 32691 A UY32691 A UY 32691A UY 0001032691 A UY0001032691 A UY 0001032691A UY 32691 A UY32691 A UY 32691A UY 32691 A UY32691 A UY 32691A
Authority
UY
Uruguay
Prior art keywords
imidazo
quinolinone
compounds
treatment
diseases
Prior art date
Application number
UY0001032691A
Other languages
English (en)
Inventor
Frederic Stauffer
Imbach Patricia
Furet Pascal
Mah Robert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY32691A publication Critical patent/UY32691A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención refiere a : uso de compuestos de 1H-imidazo-[4,5-c]-quinolinona, sales de los mismos en el tratamiento de las enfermedades dependientes de cinasa de proteína y/o de lípido, elaboración de preparaciones farmacéuticas para el tratamiento de estas enfermedades; compuestos de 1H-imidazo-[4,5,c]-quinolinona para utilizarse en el tratamiento de las enfermedades dependientes de cinasa de proteína y/o de lípido; método para el tratamiento contra estas enfermedades, el cual comprende administrar los compuestos de 1H-imidazo-[4,5-c]-quinolinona a un animal de sangre caliente, preparaciones farmacéuticas que comprenden un compuesto de 1H-imidazo-[4,5-c]-quinolinona, compuestos novedosos de 1H-imidazo-[4,5-c]-quinolinona, compuestos novedosos de 1H-imidazo-[4,5-c]-quinolinona, proceso para la preparación de los compuestos novedosos de 1H-imidazo-[4,5-c]-quinolinona.
UY0001032691A 2009-06-04 2010-06-04 Compuestos de 1h-imidazo-[4,5-c]-quinolinona UY32691A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21783609P 2009-06-04 2009-06-04

Publications (1)

Publication Number Publication Date
UY32691A true UY32691A (es) 2011-01-31

Family

ID=42670520

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032691A UY32691A (es) 2009-06-04 2010-06-04 Compuestos de 1h-imidazo-[4,5-c]-quinolinona

Country Status (8)

Country Link
US (1) US20100311714A1 (es)
EP (1) EP2438063A1 (es)
JP (1) JP2012528829A (es)
CN (1) CN102803259A (es)
AR (1) AR076968A1 (es)
TW (1) TW201100420A (es)
UY (1) UY32691A (es)
WO (1) WO2010139747A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012008049A (es) * 2010-01-12 2012-08-01 Hoffmann La Roche Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,.
DE102010035744A1 (de) * 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
EP2648733A1 (en) 2010-12-06 2013-10-16 Piramal Enterprises Limited Substituted imidazoquinoline derivatives
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
WO2013016411A1 (en) * 2011-07-28 2013-01-31 Garry Robert Smith Novel fluorinated cyclic sulfamides exhibiting neuroprotective action and their method of use
CN103030637A (zh) * 2011-10-10 2013-04-10 上海恒瑞医药有限公司 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用
WO2014141118A1 (en) * 2013-03-14 2014-09-18 Piramal Enterprises Limited Imidazo[4,5-c]quinoline derivatives and uses thereof
JP6606428B2 (ja) * 2013-10-11 2019-11-13 国立大学法人 東京医科歯科大学 脊髄小脳変性症を予防又は治療するための薬剤
NO2714752T3 (es) 2014-05-08 2018-04-21
SI3560924T1 (sl) 2015-04-02 2021-08-31 Merck Patent Gmbh Imidazolonilkinolini in njihova uporaba kot zaviralci ATM-kinaze
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519406D0 (en) * 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
GB201604182D0 (en) * 2016-03-11 2016-04-27 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
BR112019007594A2 (pt) 2016-10-13 2019-07-02 Loyola University Of Chicago método para bloquear a transmissão do parasita da malária
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
EP4034094A4 (en) * 2019-09-23 2024-01-24 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. PHOSPHODIESTERASE INHIBITORS AND THEIR USE
US20230014730A1 (en) 2019-09-23 2023-01-19 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20090082387A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched nvp-bez234
WO2010038165A1 (en) * 2008-09-30 2010-04-08 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions

Also Published As

Publication number Publication date
TW201100420A (en) 2011-01-01
AR076968A1 (es) 2011-07-20
US20100311714A1 (en) 2010-12-09
CN102803259A (zh) 2012-11-28
EP2438063A1 (en) 2012-04-11
JP2012528829A (ja) 2012-11-15
WO2010139747A1 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
UY32691A (es) Compuestos de 1h-imidazo-[4,5-c]-quinolinona
UY32682A (es) "derivados de 1h-imidazo-[4,5-c]-quinolinona"
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
GT201400253A (es) Derivados de benzamida para la inhibición de la actividad de abl1, abl2 y bcr-abl1
CU20100062A7 (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteínas quinasas b
ECSP14006132A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
AR091876A1 (es) Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
ECSP077235A (es) Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
DOP2010000242A (es) Pirrolo[2,3-d]piridinas y usos de las mismas como inhibidores de cinasa de tirosina
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
CU20140037A7 (es) Derivados de estra- 1,3,5(10), 16- tetraen- 3- carboximida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
DOP2005000051A (es) Oxadiazolonas, procedimientos para su preparacion y su uso como productos farmaceuticos
CR20150390A (es) Inhibidores de la yodoproteina basada en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1-h)-ona-asociada a la fosfolipasa a2 (lp-pla2)
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
UY31839A (es) Compuestos
UY28209A1 (es) Derivados de aminoácidos con cicloalquilo, procedimiento para su preparación y su uso como medicamentos.
UY29846A1 (es) N-(1,3,4)-tiadiazol-2-il-bencensulfonamidas, procesos para su preparación y su uso como productos farmacéuticos
UY29308A1 (es) Derivado de quinolina, su uso, preparación y medicamento que lo contiene
PA8596701A1 (es) Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos
CU20080041A7 (es) Compuestos terapéuticos
ECSP066772A (es) Compuestos de pirazolina sustituidos para reducir trigliceridos en la sangre
ES2472115R2 (es) Utilización de derivados bicíclicos de 1-desoxigalactonojirimicina en la preparación de un medicamento para el tratamiento de enfermedades relacionadas con beta-enzimas galactosidasas lisosómicas mutantes humanas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190206